# Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Source: https://onco.cc/trials/nct04098744/  
OnCo record `nct04098744` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Artesunate vaginal insert in vaginal cancer, run by Frantz Viral Therapeutics, LLC, now recruiting.

## Summary

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) is a phase 2 interventional study registered as NCT04098744 by Frantz Viral Therapeutics, LLC, with 78 participants planned, started 2020-09-09 and due to reach its primary completion in 2026-07-31. Interventions recorded: Artesunate vaginal insert and Placebo vaginal insert.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04098744
- Phase: 2
- Setting: A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3)
- Sponsor: Frantz Viral Therapeutics, LLC
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT04098744: https://clinicaltrials.gov/study/NCT04098744

## Connected records

- cancers: [Vaginal cancer](https://onco.cc/cancers/vaginal/)

---
JSON: https://onco.cc/api/v1/entities/nct04098744.json